Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Raw Materials (2023 - 2025)

Historic Raw Materials for Cytosorbents (CTSO) over the last 3 years, with Q3 2025 value amounting to $565000.0.

  • Cytosorbents' Raw Materials changed N/A to $565000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $565000.0, marking a year-over-year change of. This contributed to the annual value of $570000.0 for FY2024, which is 1688.55% down from last year.
  • Per Cytosorbents' latest filing, its Raw Materials stood at $565000.0 for Q3 2025.
  • In the past 5 years, Cytosorbents' Raw Materials registered a high of $685801.0 during Q4 2023, and its lowest value of $491000.0 during Q2 2025.
  • For the 3-year period, Cytosorbents' Raw Materials averaged around $571721.2, with its median value being $565000.0 (2025).
  • The largest annual percentage gain for Cytosorbents' Raw Materials in the last 5 years was 1688.55% (2024), contrasted with its biggest fall of 1688.55% (2024).
  • Cytosorbents' Raw Materials (Quarter) stood at $685801.0 in 2023, then dropped by 16.89% to $570000.0 in 2024, then decreased by 0.88% to $565000.0 in 2025.
  • Its last three reported values are $565000.0 in Q3 2025, $491000.0 for Q2 2025, and $546805.0 during Q1 2025.